Skip to main content
Erschienen in: Current Atherosclerosis Reports 6/2010

01.11.2010

Strategies in Stable Ischemic Heart Disease: Lessons from the COURAGE and BARI-2D Trials

verfasst von: Stanley F. Fernandez, William E. Boden

Erschienen in: Current Atherosclerosis Reports | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

There is a continuing debate regarding the most effective strategy for treating stable ischemic heart disease (SIHD). Conflicting data have emerged from several small, randomized controlled trials and meta-analyses regarding the benefits of early revascularization in SIHD. Two recent multicenter, randomized trials, the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial and the Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes (BARI-2D) trial, compared two management strategies in SIHD—an initial conservative approach with optimal medical therapy (OMT) versus a strategy of early revascularization in combination with OMT. COURAGE randomized SIHD patients who were candidates for percutaneous coronary intervention (PCI) to either a strategy of early PCI in combination with OMT or OMT alone, whereas BARI-2D randomized diabetic patients with coronary artery disease to either early revascularization (PCI or coronary artery bypass surgery [CABG]) versus OMT. This review examines the principal findings of these trials, with discussion of their strengths, limitations, and applicability to the general population. The results support the hypothesis that in patients with SIHD, early revascularization with PCI in combination with OMT is not superior to OMT alone in reducing mortality and other major cardiovascular events. Subset analysis from BARI-2D did suggest that early CABG, although it did not reduce mortality, significantly reduced the rate of nonfatal myocardial infarction compared with an initial OMT approach. Based on these data, the majority of patients with SIHD should be managed initially with medical therapy, a strategy that is also the most cost effective. Revascularization can be considered for patients with severe or refractory symptoms despite a trial of medical therapy. For diabetic patients who have extensive coronary artery disease, early revascularization with CABG may be reasonable.
Literatur
1.
Zurück zum Zitat Keeley EC, Boura JA, Grines CL: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003, 361:13–20.CrossRefPubMed Keeley EC, Boura JA, Grines CL: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003, 361:13–20.CrossRefPubMed
2.
Zurück zum Zitat Antman EM, Armstrong PW, Bates ER, et al.: 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008, 117:296–329.CrossRefPubMed Antman EM, Armstrong PW, Bates ER, et al.: 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008, 117:296–329.CrossRefPubMed
3.
Zurück zum Zitat Mehta SR, Cannon CP, Fox KA, et al.: Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 2005, 293:2908–2917.CrossRefPubMed Mehta SR, Cannon CP, Fox KA, et al.: Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 2005, 293:2908–2917.CrossRefPubMed
5.
Zurück zum Zitat • Boden WE, O’Rourke RA, Teo KK, et al.: Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007, 356:1503–1516. This article is the first publication from the COURAGE trial demonstrating the absence of incremental benefit of early PCI over OMT in overall survival rate.CrossRefPubMed • Boden WE, O’Rourke RA, Teo KK, et al.: Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007, 356:1503–1516. This article is the first publication from the COURAGE trial demonstrating the absence of incremental benefit of early PCI over OMT in overall survival rate.CrossRefPubMed
6.
Zurück zum Zitat • The BARI 2D Study Group: A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009, 360:2503–2515. This article is the first publication from the BARI-2D trial demonstrating the absence of incremental benefit of early revascularization (PCI and CABG) over OMT in overall survival rate. The early CABG group demonstrated reduced nonfatal MI over the OMT group. • The BARI 2D Study Group: A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009, 360:2503–2515. This article is the first publication from the BARI-2D trial demonstrating the absence of incremental benefit of early revascularization (PCI and CABG) over OMT in overall survival rate. The early CABG group demonstrated reduced nonfatal MI over the OMT group.
7.
Zurück zum Zitat Henderson RA, Pocock SJ, Clayton TC, et al.: Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol 2003, 42:1161–1170.CrossRefPubMed Henderson RA, Pocock SJ, Clayton TC, et al.: Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol 2003, 42:1161–1170.CrossRefPubMed
8.
Zurück zum Zitat TIME Investigators: Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. Lancet 2001, 358:951–957.CrossRef TIME Investigators: Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. Lancet 2001, 358:951–957.CrossRef
9.
Zurück zum Zitat Hueb W, Soares PR, Gersh BJ, et al.: The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol 2004, 43:1743–1751.CrossRefPubMed Hueb W, Soares PR, Gersh BJ, et al.: The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol 2004, 43:1743–1751.CrossRefPubMed
10.
Zurück zum Zitat RITA-2 trial participants: Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. Lancet 1997, 350:461–468.CrossRef RITA-2 trial participants: Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. Lancet 1997, 350:461–468.CrossRef
11.
Zurück zum Zitat Hueb W, Lopes, NH, Gersh BJ, et al.: Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2007, 115:1082–1089.CrossRefPubMed Hueb W, Lopes, NH, Gersh BJ, et al.: Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2007, 115:1082–1089.CrossRefPubMed
12.
Zurück zum Zitat • Katritsis DG, Ioannidis JP: Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation 2005, 111:2906–2912. This article is an important meta-analysis published prior to the release of COURAGE and BARI-2D data that directly compared the utility of early revascularization versus medical therapy in SIHD patients.CrossRefPubMed • Katritsis DG, Ioannidis JP: Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation 2005, 111:2906–2912. This article is an important meta-analysis published prior to the release of COURAGE and BARI-2D data that directly compared the utility of early revascularization versus medical therapy in SIHD patients.CrossRefPubMed
13.
Zurück zum Zitat Boden WE, O’Rourke RA, Teo KK, et al.: The evolving pattern of symptomatic coronary artery disease in the United States and Canada: baseline characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial. Am J Cardiol 2007, 99:208–212.CrossRefPubMed Boden WE, O’Rourke RA, Teo KK, et al.: The evolving pattern of symptomatic coronary artery disease in the United States and Canada: baseline characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial. Am J Cardiol 2007, 99:208–212.CrossRefPubMed
14.
Zurück zum Zitat Wild S, Roglic G, Green A, et al.: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047–1053.CrossRef Wild S, Roglic G, Green A, et al.: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047–1053.CrossRef
15.
Zurück zum Zitat Garcia MJ, McNamara PM, Gordon T, et al.: Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974, 23:105–111.PubMed Garcia MJ, McNamara PM, Gordon T, et al.: Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974, 23:105–111.PubMed
16.
Zurück zum Zitat Gibbons RJ, Abrams J, Chatterjee K, et al.: ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003, 107:149–158.CrossRefPubMed Gibbons RJ, Abrams J, Chatterjee K, et al.: ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003, 107:149–158.CrossRefPubMed
17.
Zurück zum Zitat Fox K, Garcia MA, Ardiddino D, et al.: Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006, 27:1341–1381.CrossRefPubMed Fox K, Garcia MA, Ardiddino D, et al.: Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006, 27:1341–1381.CrossRefPubMed
18.
Zurück zum Zitat Cecil WT, Kasteridis P, Barnes JW Jr, et al.: A meta-analysis update: percutaneous coronary interventions. Am J Manag Care 2008, 14:521–528.PubMed Cecil WT, Kasteridis P, Barnes JW Jr, et al.: A meta-analysis update: percutaneous coronary interventions. Am J Manag Care 2008, 14:521–528.PubMed
19.
Zurück zum Zitat • Schomig A, Mehilli J, de Waha A, et al.: A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease. J Am Coll Cardiol 2008, 52:894–904. This article is a large meta-analysis on therapeutic approaches of stable CAD patients. It demonstrated that PCI is associated with significant mortality reduction compared with medical therapy.CrossRefPubMed • Schomig A, Mehilli J, de Waha A, et al.: A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease. J Am Coll Cardiol 2008, 52:894–904. This article is a large meta-analysis on therapeutic approaches of stable CAD patients. It demonstrated that PCI is associated with significant mortality reduction compared with medical therapy.CrossRefPubMed
20.
Zurück zum Zitat Hochman JS, Lamas GA, Buller CE, et al.: Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 2006, 355:2395–2407.CrossRefPubMed Hochman JS, Lamas GA, Buller CE, et al.: Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 2006, 355:2395–2407.CrossRefPubMed
21.
Zurück zum Zitat • Wijeysundera HC, Ko DT: Does percutaneous coronary intervention reduce mortality in patients with stable chronic angina: are we talking about apples and oranges? Circ Cardiovasc Qual Outcomes 2009, 2:123–126. This article analyzed the review by Schomig et al. [19•] and suggested that inclusion of unstable CAD patients in the analysis may have contributed to the improved outcome seen with PCI. CrossRefPubMed • Wijeysundera HC, Ko DT: Does percutaneous coronary intervention reduce mortality in patients with stable chronic angina: are we talking about apples and oranges? Circ Cardiovasc Qual Outcomes 2009, 2:123–126. This article analyzed the review by Schomig et al. [19•] and suggested that inclusion of unstable CAD patients in the analysis may have contributed to the improved outcome seen with PCI. CrossRefPubMed
22.
Zurück zum Zitat Hlatky MA, Boothroyd DB, Melsop KA, et al.: Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. Circulation 2009, 120:2550–2558.CrossRefPubMed Hlatky MA, Boothroyd DB, Melsop KA, et al.: Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. Circulation 2009, 120:2550–2558.CrossRefPubMed
23.
Zurück zum Zitat Naghavi M, Libby P, Falk E, et al.: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003, 108:1664–1672.CrossRefPubMed Naghavi M, Libby P, Falk E, et al.: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003, 108:1664–1672.CrossRefPubMed
24.
Zurück zum Zitat Pfisterer M, Buser P, Osswald S, et al.: Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. JAMA 2003, 289:1117–1123.CrossRefPubMed Pfisterer M, Buser P, Osswald S, et al.: Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. JAMA 2003, 289:1117–1123.CrossRefPubMed
25.
Zurück zum Zitat Pfisterer M, and Trial of Invasive versus Medical therapy in Elderly patients Investigators: Long-term outcome in elderly patients with chronic angina managed invasively versus by optimized medical therapy: four-year follow-up of the randomized Trial of Invasive versus Medical therapy in Elderly patients (TIME). Circulation 2004, 110:1213–1218.CrossRefPubMed Pfisterer M, and Trial of Invasive versus Medical therapy in Elderly patients Investigators: Long-term outcome in elderly patients with chronic angina managed invasively versus by optimized medical therapy: four-year follow-up of the randomized Trial of Invasive versus Medical therapy in Elderly patients (TIME). Circulation 2004, 110:1213–1218.CrossRefPubMed
26.
Zurück zum Zitat Valgimigli M, Serruys PW, Tsuchida K, et al.: Cyphering the complexity of coronary artery disease using the syntax score to predict clinical outcome in patients with three-vessel lumen obstruction undergoing percutaneous coronary intervention. Am J Cardiol 2007, 99:1072–1081.CrossRefPubMed Valgimigli M, Serruys PW, Tsuchida K, et al.: Cyphering the complexity of coronary artery disease using the syntax score to predict clinical outcome in patients with three-vessel lumen obstruction undergoing percutaneous coronary intervention. Am J Cardiol 2007, 99:1072–1081.CrossRefPubMed
27.
Zurück zum Zitat Hachamovitch R, Hayes SW, Friedman JD, et al.: Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003, 107:2900–2907.CrossRefPubMed Hachamovitch R, Hayes SW, Friedman JD, et al.: Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003, 107:2900–2907.CrossRefPubMed
28.
Zurück zum Zitat Shaw LJ, Berman DS, Maron DJ, et al.: Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008,117:1283–1291.CrossRefPubMed Shaw LJ, Berman DS, Maron DJ, et al.: Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008,117:1283–1291.CrossRefPubMed
29.
Zurück zum Zitat Nissen SE, Nicholls SJ, Sipahi I, et al.: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006, 295:1556–1565.CrossRefPubMed Nissen SE, Nicholls SJ, Sipahi I, et al.: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006, 295:1556–1565.CrossRefPubMed
30.
Zurück zum Zitat Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071–1080.CrossRefPubMed Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071–1080.CrossRefPubMed
31.
Zurück zum Zitat Jensen LO, Thayssen P, Pedersen KE, et al.: Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation 2004, 110:265–270.CrossRefPubMed Jensen LO, Thayssen P, Pedersen KE, et al.: Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation 2004, 110:265–270.CrossRefPubMed
32.
Zurück zum Zitat Farkouh ME, Dangas G, Leon MB, et al.: Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. Am Heart J 2008, 155:215–223.CrossRefPubMed Farkouh ME, Dangas G, Leon MB, et al.: Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. Am Heart J 2008, 155:215–223.CrossRefPubMed
Metadaten
Titel
Strategies in Stable Ischemic Heart Disease: Lessons from the COURAGE and BARI-2D Trials
verfasst von
Stanley F. Fernandez
William E. Boden
Publikationsdatum
01.11.2010
Verlag
Current Science Inc.
Erschienen in
Current Atherosclerosis Reports / Ausgabe 6/2010
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-010-0135-2

Weitere Artikel der Ausgabe 6/2010

Current Atherosclerosis Reports 6/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.